KTH-Royal Institute of Technology in Stockholm is the largest and oldest technical university in Sweden. Science for Life Laboratory (SciLifeLab) is a collaboration between KTH, Stockholm University, Karolinska Institutet and Uppsala University for high-throughput molecular biosciences.

The Affinity Proteomics group at SciLifeLab, School of Biotechnology at KTH develops and applies targeted and non-targeted microarray-based strategies using the antigens and antibodies available through the Human Protein Atlas. Immunoassays developed and optimized on these arrays are used for high-throughput analysis of body fluids for disease biomarker discovery. Here, the antibodies or antigens are used to create arrays, which allow for highly multiplex analysis of protein or autoantibody profiles.

Main tasks attributed in the project

Partner KTH will participate in WPs 02 and 05.

Main personnel involved in the project

Peter Nilsson, the KTH PI, is a Professor in Proteomics at SciLifeLab, KTH – Royal Institute of Technology. He has since 2002 been heading the Protein Microarray group within the Human Protein Atlas project. He is the executive director of Affinity Proteomics national platform at SciLifeLab Stockholm and the site director of the Human Protein Atlas at SciLifeLab Stockholm. He is also the vice dean of the School of Biotechnology at KTH. The main research focus is within development and utilization of various protein microarray technologies for antigen and antibody based proteomic profiling and biomarker discovery. Please see publicationslist for a complete list of publications

David Just is a 3rd year PhD student in Prof Peter Nilsson’s lab where his research focus so far has been on the relationship between autoimmunity and psychiatric disorders. David has applied novel analytical techniques to investigate antibody signatures in schizophrenia and psychosis. As part of RELENT, David will implement these techniques in patients with ANCA-associated vasculitis, Giant Cell Arthritis and Polymyalgia Rheumatica, where the aim is to identify auto-antibody profiles associated with disease activity and response to treatment. This should facilitate the identification of novel therapeutic targets and personalize treatment.

Elisa Pin is a post-doctoral fellow at SciLifeLab, KTH – Royal Institute of Technology. She has a MSc degree in Medical Biology from the University of Padua (Italy) and a Specialization degree in Clinical Pathology from the University of Udine (Italy). She has a background in genetics and virology, and in the last five years her research focused on protein biomarkers discovery and validation. She participated to several clinical research studies. Please see publicationslist for a list of publications